Understanding Differences in HIV/HCV Patients Accessing Hepatitis C Treatment

Co-infection with HIV (Human Immunodeficiency Virus) and HCV (Hepatitis C Virus) presents significant challenges, accelerating liver disease progression and increasing mortality. Despite the availability of highly effective direct-acting antivirals (DAAs) that can cure HCV, many co-infected individuals do not complete the full 'HCV care cascade' – the series of steps from diagnosis to treatment and cure. This study aims to identify specific population characteristics that differentiate HIV/HCV co-infected patients who have achieved HCV cure from those who have not yet initiated treatment.

The analysis revealed several significant disparities between cured and untreated HIV/HCV co-infected patients. Cured patients were found to be significantly older (mean age 55.2 years vs. 48.7 years, p<0.001) and had a higher prevalence of stable housing (85% vs. 62%, p<0.001). Furthermore, the group that achieved HCV cure demonstrated lower rates of active injection drug use (15% vs. 48%, p<0.001) and fewer documented mental health comorbidities (28% vs. 55%, p<0.001) compared to the untreated cohort. The most striking finding was that patients who had not yet initiated HCV treatment were 3.5 times more likely to have a history of unstable housing and active substance use, highlighting critical barriers to care. These differences suggest that social and behavioral factors play a substantial role in navigating the HCV care cascade, with untreated patients presenting a higher burden of psychosocial challenges.